Yahoo Finance analysis indicates that pharmaceutical giant AbbVie has returned $62 billion to shareholders through dividends and share buybacks over the past five years, representing 13.4% of its current market capitalization. During the same period, AbbVie's total return reached 161%, nearly double that of the S&P 500 index. Its strong cash flow is primarily driven by its immunology product portfolio, with SKYRIZI projected to achieve $21.7 billion in full-year global revenue.